Epigenetic Therapeutics: Global Markets

Abstract
Report Scope:

This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

This report, however, does not cover epigenetic diagnostic assays and instruments.

Report Includes:

- 77 tables
- A comprehensive overview of the global markets for epigenetic therapeutics
- Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
- In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
- Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
- A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
- Review of patent trends and research publications for innovations in the genome-editing technologies
- Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
- Analysis of the competitive environment and market opportunities based on the company’s business strategies, product mapping, and operational integration
- Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte

Content
Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Highlights of the Market for Epigenetic Therapeutics
Chapter 3 Market Overview and Definitions
Overview
Epigenetics
Chapter 4 Market Trends
Market Drivers
Aging Population
Risk of Cancer in Major Countries
Penetration of Targeted Medicine in Emerging Markets
Market Opportunity
Market Restraints
Chapter 5 Market Breakdown by Product Type
Introduction
PRAP Inhibitors
Kinase Inhibitors
IDH Inhibitors
HDAC Inhibitors
DNMT Inhibitors
KMT Inhibitors
Chapter 6 Impact of COVID-19
Introduction
Impact of COVID-19 on the Medical Devices and Pharmaceutical Industries
Decline/Delay in Elective Procedures
Impact of COVID-19 on Medical Device and Pharmaceutical Product Segments
Impact of COVID-19 on Epigenetic Therapeutics Markets
Chapter 7 Market Breakdown by Region
Market Overview and Discussion
North America
Latin America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Emerging/Upcoming Technologies
CRISPR
Antibody Drug Conjugates
Multitargeting Agents
Chapter 9 Competitive Landscape
Industry Scenario
Company Shares
Chapter 10 Patent Analysis
Patent Analysis, by Manufacturer
Chapter 11 Pipeline Analysis
Clinical Trials Scenario
Chapter 12 Company Profiles
ASTRAZENECA
BRISTOL-MYERS SQUIBB
CLOVIS ONCOLOGY
GSK PLC
INCYTE
IPSEN
SEAGEN
SERVIER LABORATORIES, LTD.
Chapter 13 Appendix: Acronyms